Peramivir for the treatment of influenza

Avinash K. Shetty, Leigh A. Peek

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Peramivir (BioCryst Pharmaceuticals) is a novel investigational intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. Peramivir is created by a structure-based drug design and consists of a cyclopentane backbone with a positively charged guanidinyl group and lipophilic side chains. Peramivir was made available in the USA through the Emergency Investigational New Drug regulations and under an Emergency Use Authorization for hospitalized patients with known or suspected influenza during the 2009 H1N1 influenza pandemic. In trials involving ambulatory adult subjects, intravenous peramivir is safe and has a pharmacokinetic profile that supports once-daily dosing. The drug is licensed in Japan and South Korea and is currently undergoing Phase III trials in the USA. Viral resistance mechanisms to peramivir have not been fully delineated and ongoing surveillance is important. Given the serious health threat of influenza at all ages and limitations in vaccine delivery, peramivir is a promising addition to the currently limited treatment options for the treatment of severe influenza infection.

Original languageEnglish
Pages (from-to)123-143
Number of pages21
JournalExpert Review of Anti-Infective Therapy
Volume10
Issue number2
DOIs
Publication statusPublished - 01-02-2012
Externally publishedYes

Fingerprint

Human Influenza
Emergencies
Therapeutics
Investigational Drugs
Influenza B virus
Cyclopentanes
Republic of Korea
Drug and Narcotic Control
Drug Design
Influenza A virus
Neuraminidase
Pandemics
Pharmaceutical Preparations
Antiviral Agents
peramivir
Japan
Vaccines
Pharmacokinetics
Health
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Shetty, Avinash K. ; Peek, Leigh A. / Peramivir for the treatment of influenza. In: Expert Review of Anti-Infective Therapy. 2012 ; Vol. 10, No. 2. pp. 123-143.
@article{96def3dc3e7a4b0a9e12d18b2c2ef42d,
title = "Peramivir for the treatment of influenza",
abstract = "Peramivir (BioCryst Pharmaceuticals) is a novel investigational intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. Peramivir is created by a structure-based drug design and consists of a cyclopentane backbone with a positively charged guanidinyl group and lipophilic side chains. Peramivir was made available in the USA through the Emergency Investigational New Drug regulations and under an Emergency Use Authorization for hospitalized patients with known or suspected influenza during the 2009 H1N1 influenza pandemic. In trials involving ambulatory adult subjects, intravenous peramivir is safe and has a pharmacokinetic profile that supports once-daily dosing. The drug is licensed in Japan and South Korea and is currently undergoing Phase III trials in the USA. Viral resistance mechanisms to peramivir have not been fully delineated and ongoing surveillance is important. Given the serious health threat of influenza at all ages and limitations in vaccine delivery, peramivir is a promising addition to the currently limited treatment options for the treatment of severe influenza infection.",
author = "Shetty, {Avinash K.} and Peek, {Leigh A.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1586/eri.11.174",
language = "English",
volume = "10",
pages = "123--143",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "2",

}

Peramivir for the treatment of influenza. / Shetty, Avinash K.; Peek, Leigh A.

In: Expert Review of Anti-Infective Therapy, Vol. 10, No. 2, 01.02.2012, p. 123-143.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peramivir for the treatment of influenza

AU - Shetty, Avinash K.

AU - Peek, Leigh A.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Peramivir (BioCryst Pharmaceuticals) is a novel investigational intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. Peramivir is created by a structure-based drug design and consists of a cyclopentane backbone with a positively charged guanidinyl group and lipophilic side chains. Peramivir was made available in the USA through the Emergency Investigational New Drug regulations and under an Emergency Use Authorization for hospitalized patients with known or suspected influenza during the 2009 H1N1 influenza pandemic. In trials involving ambulatory adult subjects, intravenous peramivir is safe and has a pharmacokinetic profile that supports once-daily dosing. The drug is licensed in Japan and South Korea and is currently undergoing Phase III trials in the USA. Viral resistance mechanisms to peramivir have not been fully delineated and ongoing surveillance is important. Given the serious health threat of influenza at all ages and limitations in vaccine delivery, peramivir is a promising addition to the currently limited treatment options for the treatment of severe influenza infection.

AB - Peramivir (BioCryst Pharmaceuticals) is a novel investigational intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. Peramivir is created by a structure-based drug design and consists of a cyclopentane backbone with a positively charged guanidinyl group and lipophilic side chains. Peramivir was made available in the USA through the Emergency Investigational New Drug regulations and under an Emergency Use Authorization for hospitalized patients with known or suspected influenza during the 2009 H1N1 influenza pandemic. In trials involving ambulatory adult subjects, intravenous peramivir is safe and has a pharmacokinetic profile that supports once-daily dosing. The drug is licensed in Japan and South Korea and is currently undergoing Phase III trials in the USA. Viral resistance mechanisms to peramivir have not been fully delineated and ongoing surveillance is important. Given the serious health threat of influenza at all ages and limitations in vaccine delivery, peramivir is a promising addition to the currently limited treatment options for the treatment of severe influenza infection.

UR - http://www.scopus.com/inward/record.url?scp=84857509236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857509236&partnerID=8YFLogxK

U2 - 10.1586/eri.11.174

DO - 10.1586/eri.11.174

M3 - Article

C2 - 22339187

AN - SCOPUS:84857509236

VL - 10

SP - 123

EP - 143

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 2

ER -